Abstract:Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion and the exposure of infiltrating CAR T-cells to a panoply of immune suppressive checkpoint molecules, cytokines, and metabolic stresses that are not conducive to efficient immune reactions and can thereby render these cells anergic, exhausted, or apoptotic. This mini-review summarizes these hurdles and describes some recent approaches and innovations to genetically re-engineer CAR T-cells to counter inhibitory influences found in the tumor microenvironment. Novel immunotherapy drug combinations to potentiate the activity of CAR T-cells are also discussed. As our understanding of the immune landscape of tumors improves and our repertoire of immunotherapeutic drugs expands, it is envisaged that the efficacy of CAR T-cells against solid tumors might be potentiated using combination therapies, which it is hoped may lead to meaningful improvements in clinical outcome for patients with refractory solid malignancies.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

Chimeric Antigen Receptor Engineered Innate Immune Cells in Cancer Immunotherapy

Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects.

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

A New Insight in Chimeric Antigen Receptor-Engineered T Cells for Cancer Immunotherapy

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer

Synthetic immunology: T-cell engineering and adoptive immunotherapy

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells